One-hundred million red: The latest clinical results of the innovative drug deuterated benzbromarone (AR882) for the treatment of gout stones were published at ACR 2025.

Jin10 data reported on October 29th, Yipinhong announced that the latest clinical results of its innovative gout drug deuterated benzbromarone (AR882) for the treatment of gout stones were released at ACR2025 (American College of Rheumatology Annual Meeting). Clinical conclusions show that for patients with newly treated and refractory gout stones, monotherapy with deuterated benzbromarone or combination therapy with allopurinol can effectively drop sUA, reduce urate crystal burden, and achieve a high complete dissolution rate of targeted gout stones. Monotherapy or combination therapy with deuterated benzbromarone can provide a more effective treatment option for patients with chronic gout stones who have poor efficacy with existing treatment regimens.

View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments
Trade Crypto Anywhere Anytime
qrCode
Scan to download Gate App
Community
English
  • 简体中文
  • English
  • Tiếng Việt
  • 繁體中文
  • Español
  • Русский
  • Français (Afrique)
  • Português (Portugal)
  • Bahasa Indonesia
  • 日本語
  • بالعربية
  • Українська
  • Português (Brasil)